Holen Sie sich die Stockscreener-App
37.50
2.66%
0.97
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect - ACCESS Newswire
Will Corcept Therapeutics Incorporated (HTD) stock outperform benchmarksWeekly Market Outlook & AI Powered Buy/Sell Recommendations - ulpravda.ru
Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter - Finviz
Is Corcept Therapeutics Incorporated stock positioned for long term growthJuly 2025 Rallies & Capital Protection Trading Alerts - ulpravda.ru
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Guyer, Corcept therapeutics officer, sells $703k in shares By Investing.com - Investing.com Canada
CORT ALERT: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated for Possible Securities Fraud Violations - ACCESS Newswire
Is Corcept Therapeutics Incorporated stock in correction or buying zoneDip Buying & High Accuracy Investment Signals - ulpravda.ru
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics ... - Bluefield Daily Telegraph
CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Why Corcept Therapeutics Incorporated stock is a must watch in 2025 - ulpravda.ru
Published on: 2026-01-08 22:12:30 - ulpravda.ru
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
Corcept Therapeutics Shares Plunge Over 50% Following FDA Complete Response Letter - Intellectia AI
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman - GlobeNewswire
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman - GlobeNewswire Inc.
Corcept sinks after FDA rejects drug to treat hypertension - MSN
Buybacks Report: Is Corcept Therapeutics Incorporated HTD stock among top earnings playsJuly 2025 Trade Ideas & Safe Swing Trade Setups - moha.gov.vn
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT) - TMX Newsfile
Analysts see 70% upside potential in Corcept Therapeutics (CORT) stock - MSN
Fraud Investigation Opened: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) on Behalf of Shareholders - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
Corcept Therapeutics Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50%Hagens Berman - Investing News Network
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - GlobeNewswire Inc.
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50%Hagens Berman - Finviz
Potential Securities Fraud: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) - ACCESS Newswire
CORT ACTIVE INVESTIGATION: Lost Money on Corcept Therapeutics Incorporated? Contact Levi & Korsinsky Now - ACCESS Newswire
CORCEPT THERAPEUTICS is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
Corcept Therapeutics Incorporated Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsCORT - ACCESS Newswire
Why Corcept (CORT) Stock Is Trading Lower Today - Finviz
Daily News - FinancialContent
Why Is Crinetics Pharma Stock Soaring Monday?Crinetics Pharmaceuticals (NASDAQ:CRNX) - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Shares Down 6.9% Following Analyst Downgrade - MarketBeat
Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? - Yahoo Finance
1 Healthcare Stock to Target This Week and 2 We Turn Down - Finviz
What is HC Wainwright's Estimate for CORT FY2030 Earnings? - MarketBeat
Why is CORT stock falling today? - MSN
Fraud Investigation: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) on Behalf of Shareholders - ACCESS Newswire
Why Is CORT Stock Falling Today? - Asianet Newsable
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations - NewMediaWire
Synergy Asset Management LLC Raises Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
About Us - FinancialContent
Why Corcept Therapeutics plummeted by 50% today - MSN
US FDA declines to approve Corcept's drug for rare hormonal disorder - ETPharma.com
Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) Over Potential Securities Fraud Allegations - ACCESS Newswire
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next - ts2.tech
Corcept setback as relacorilant filing for hypercortisolism is rejected - The Pharma Letter
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism - Finviz
FDA rejects relacorilant for Cushing’s-related high blood pressure - Cushing's Disease News
Corcept Therapeutics (NASDAQ:CORT) Trading Up 9.7%Here's What Happened - MarketBeat
The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away - Barchart.com
FinancialContentKaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations - FinancialContent
Implied Volatility Surging for Corcept Stock Options - Yahoo Finance
Canaccord Genuity Adjusts Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD) - The Globe and Mail
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Given New $99.00 Price Target at Canaccord Genuity Group - MarketBeat
Corcept Therapeutics stock price target lowered to $90 at H.C. Wainwright - Investing.com Canada
Corcept Therapeutics stock price target cut by Canaccord on FDA setback - Investing.com Canada
Corcept Therapeutics (CORT) Faces FDA Setback, But Growth Potent - GuruFocus
HC Wainwright & Co. Lowers Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
FDA rejects drug for hormone disorder - medwatch.com
Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - The National Law Review
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):